135 related articles for article (PubMed ID: 18289047)
21. Antineoplastic action of 5-aza-2'-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells.
Bovenzi V; Momparler RL
Cancer Chemother Pharmacol; 2001 Jul; 48(1):71-6. PubMed ID: 11488527
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma.
Marini A; Mirmohammadsadegh A; Nambiar S; Gustrau A; Ruzicka T; Hengge UR
J Invest Dermatol; 2006 Feb; 126(2):422-31. PubMed ID: 16374457
[TBL] [Abstract][Full Text] [Related]
23. Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises.
Anestopoulos I; Kyriakou S; Tragkola V; Paraskevaidis I; Tzika E; Mitsiogianni M; Deligiorgi MV; Petrakis G; Trafalis DT; Botaitis S; Giatromanolaki A; Koukourakis MI; Franco R; Pappa A; Panayiotidis MI
Pharmacol Ther; 2022 Dec; 240():108301. PubMed ID: 36283453
[TBL] [Abstract][Full Text] [Related]
24. A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system.
Alvino E; Castiglia D; Caporali S; Pepponi R; Caporaso P; Lacal PM; Marra G; Fischer F; Zambruno G; Bonmassar E; Jiricny J; D'Atri S
Int J Oncol; 2006 Oct; 29(4):785-97. PubMed ID: 16964376
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.
Park J; Thomas S; Munster PN
Epigenomics; 2015; 7(4):641-52. PubMed ID: 26111034
[TBL] [Abstract][Full Text] [Related]
26. Epigenetics of melanoma: implications for immune-based therapies.
Fratta E; Sigalotti L; Covre A; Parisi G; Coral S; Maio M
Immunotherapy; 2013 Oct; 5(10):1103-16. PubMed ID: 24088079
[TBL] [Abstract][Full Text] [Related]
27. Targeting complex, adaptive responses in melanoma therapy.
Cheng P; Levesque MP; Dummer R; Mangana J
Cancer Treat Rev; 2020 Jun; 86():101997. PubMed ID: 32179238
[TBL] [Abstract][Full Text] [Related]
28. Epigenome-based personalized medicine in human cancer.
Yan W; Herman JG; Guo M
Epigenomics; 2016 Jan; 8(1):119-33. PubMed ID: 26344672
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment.
Egger G; Aparicio AM; Escobar SG; Jones PA
Cancer Res; 2007 Jan; 67(1):346-53. PubMed ID: 17210717
[TBL] [Abstract][Full Text] [Related]
30. VDR microRNA expression and epigenetic silencing of vitamin D signaling in melanoma cells.
Essa S; Denzer N; Mahlknecht U; Klein R; Collnot EM; Tilgen W; Reichrath J
J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):110-3. PubMed ID: 20153427
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma.
Venturelli S; Armeanu S; Pathil A; Hsieh CJ; Weiss TS; Vonthein R; Wehrmann M; Gregor M; Lauer UM; Bitzer M
Cancer; 2007 May; 109(10):2132-41. PubMed ID: 17407132
[TBL] [Abstract][Full Text] [Related]
32. DNA hypermethylation of myeloid cells, a novel therapeutic target in MDS and AML.
Müller CI; Rüter B; Koeffler HP; Lübbert M
Curr Pharm Biotechnol; 2006 Oct; 7(5):315-21. PubMed ID: 17076647
[TBL] [Abstract][Full Text] [Related]
33. Clinical development of decitabine as a prototype for an epigenetic drug program.
Rosenfeld CS
Semin Oncol; 2005 Oct; 32(5):465-72. PubMed ID: 16210087
[TBL] [Abstract][Full Text] [Related]
34. Targeting Histone Deacetylases in Malignant Melanoma: A Future Therapeutic Agent or Just Great Expectations?
Garmpis N; Damaskos C; Garmpi A; Dimitroulis D; Spartalis E; Margonis GA; Schizas D; Deskou I; Doula C; Magkouti E; Andreatos N; Antoniou EA; Nonni A; Kontzoglou K; Mantas D
Anticancer Res; 2017 Oct; 37(10):5355-5362. PubMed ID: 28982843
[TBL] [Abstract][Full Text] [Related]
35. Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells.
Meng CF; Zhu XJ; Peng G; Dai DQ
Oncol Rep; 2009 Nov; 22(5):1221-7. PubMed ID: 19787243
[TBL] [Abstract][Full Text] [Related]
36. Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT.
Christmann M; Pick M; Lage H; Schadendorf D; Kaina B
Int J Cancer; 2001 Apr; 92(1):123-9. PubMed ID: 11279615
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine).
Momparler RL
Semin Oncol; 2005 Oct; 32(5):443-51. PubMed ID: 16210084
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors.
Ungerstedt JS
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30304859
[TBL] [Abstract][Full Text] [Related]
40. MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study.
Guadagni S; Fiorentini G; Clementi M; Palumbo G; Masedu F; Deraco M; De Manzoni G; Chiominto A; Valenti M; Pellegrini C
Melanoma Res; 2017 Oct; 27(5):439-447. PubMed ID: 28486243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
